Adeno-associated virus (AAV), a prominently used vector in human gene therapy is a small, non-enveloped parvovirus consisting of a single-stranded DNA genome enclosed in a protein capsid.

AAV vector is used to transfer therapeutic genes to humans for the treatment of monogenic diseases, ocular diseases, and clinical trials of deficiencies like hemophilia and thalassemia. Its non-pathogenic nature, low immunogenicity, ability to retain long-term gene expression, and low likelihood to induce an inflammatory response make it very promising gene therapy vector.

This blog post provides a brief outlook on the importance of quantitation in AAV process development and how the innovative solutions from Gator Bio fill this gap in AAV characterization.

Importance of quantitation

Accurate quantitation of the AAV genome and capsid titer is an important step in AAV process development to ensure safe and efficacious dosing.  High vector doses of AAV due to inaccurate quantitation can lead to an inflammatory response that is dangerous for sensitive organs such as the eyes.

Conventional AAV quantitation include PCR-based methods (qPCR). The major drawback of PCR-based quantitation is that it does not provide any information on the loss of integrity in viral particles. Moreover, PCR assays are prone to contamination by salts, proteins, or plasmid DNAs, and thus pose a risk of inaccurate quantitation.

Other established immunoassays such as ELISA, and Dot blot for capsid titer quantitation are time-consuming, labor-intensive, and thus significantly impede the AAV process development cycle and its manufacturing.

Gator Bio’s solutions for accurate quantitation

Gator Bio has developed Gator^® Plus, unique plug-n-play, cost-effective high-throughput bioanalytical tool for accurate, high-sensitivity serotype quantitation in a highly parallelized, automated manner. It is based on Biolayer Interferometry (BLI) technology and uses CaptureSelect AAVX nanobody probes to bind and quantitate AAV capsid serotypes including AAV 1-8 and 10 with a dynamic range of 5×10⁶ – 1×10¹³ vp/mL. The probes are compatible with various matrices used in process development The assay developed using these probes can be used for quantitation of AAVs from harvesting stage  to final product QC  Eight channels are operational in parallel and can process up to 96 samples within less than 30 minutes, resulting in high throughput quantification. The probes render an impressive regeneration performance and are reusable up to 10 times without any loss in binding, thus saving a lot of process time and operating costs.

Integration with GatorOne^® software allows easy data analysis and sample AAV concentration measurement. It allows saving multiple standard curves needed to quantify different AAV serotypes, thereby saving the time to generate standard curves repeatedly, thus enhancing the process efficiency.

Drop us a line if you would like to know more about our quantitation solutions.

---

References:

1. Martinez-Fernandez de la Camara, C. et al. Genes 2021, 12, 601. https://doi.org/10.3390/genes12040601
2. Shmidt, A.A. et al. Pharmaceuticals 2022, 15, 23. https://doi.org/10.3390/ph15010023
3. Cui, M. et al. Molecules 2019, 24, 3973; doi:10.3390/molecules24213973
4. https://www.gatorbio.com/wp-content/uploads/2022/04/AAVX-vs-Progen-App-Note.pdf

PALO ALTO, Calif., June 1, 2022 /PRNewswire/ — Gator Bio, the next gen Biolayer Interferometry solutions company, has signed an agreement with I&L Biosystems GmbH, a distributor of innovative biomedical technology and products. The agreement will allow Gator Bio to expand rapidly its product offerings into the European Union, a key region for Gator’s growth strategy as it begins its global reach.

Dr. Hong Tan, CEO of Gator Bio, said, “I&L Biosystems has a history of bringing new and innovative technologies into market — as evidenced by its previous success in commercializing e.g., various multi-analyzer, protein purification devices, SPR instruments, and bioreactors, etc. We look forward to working with the I&L team to bring the Gator platform to users throughout the region, helping meet the demand for therapeutics development and manufacturing.”

“Gator BLI platform and a range of innovative biosensors are an important addition to I&L’s portfolio of protein characterization products, and we are very excited about the possibilities the Gator shall give our customers in characterizing antibodies, AAVs and small molecule drugs,” said Mr. Alexander M. Beljaars, CEO of I&L Biosystems GmbH. “Access to this next gen technology is key to the continued enablement of our biopharma and academia research customers across our geographies. We are very excited about helping research and manufacturing community with the novel applications in gene therapy, immune therapy and lipid nano particle development.”

The latest partnership of two companies builds on Gator Bio’s commitment to providing high-quality BLI platforms globally, recently demonstrated through a strategic partnership with BMS Korea (Bio Medical Sciences) to provide sales and services to biotherapeutics and gene therapy companies in Republic of Korea. To learn more, please visit www.gatorbio.com.

About Gator Bio, Inc.

Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio along with its sister company ET Healthcare are part of Access Medical Systems. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com.

About I&L Biosystems

I&L Biosystems is a leading distributor of innovative scientific products with the headquarter in Königswinter, Germany. The company was founded in 1991 and has been growing steadily ever since. The focus of I&L is on sales and distribution of high-quality laboratory equipment to customers and researchers in the microbiology, cell biology and biotechnology markets in almost all European countries. High quality of the products, competent advice and fast service are the basis for a long-lasting relationship with our customers and partners in industry, research and development. More than 120 employees ensure that our customers throughout Europe receive excellent support for technical or application-related questions. Visit I&L Biosystems’ website for more information: www.il-biosystems.com.

Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
[email protected]
+1 650 575 0827
Website: http://www.gatorbio.com//
LinkedIn

Biomolecular interaction analysis seeks to understand the interactions between biomolecules and the results of these interactions. This type of analysis is critical for medical research and pharmaceuticals. Here we explain some of the key principles of biomolecular interaction analysis and its applications.

Why Study Biomolecular Interaction?

Interactions between biomolecules are a critical aspect of many biological processes. Whilst some proteins function on their own, most proteins are only active in complex forms. This means that their relationships with other biomolecules such as metals, lipids, proteins, and nucleic acids are extremely important.

Biomolecular interaction analysis looks at the physical contact between protein partners as well as the functional trends in signaling and metabolic pathways. Protein interactions and molecular interactions are intrinsic to all areas of cellular process such as:

• Regulation of metabolic pathways
• Cellular motion
• Signal transduction
• Environment sensing

With so many critical processes being informed by biomolecular interaction, the right form of analysis must be chosen.

Surface Plasmon Resonance SPR

SPR is a label-free method of biomolecular interaction analysis that works by using incident light to stimulate oscillating conduction electrons between positive and negative permittivity material. SPR measures adsorption onto planar metal or onto the surface of metal nanoparticles.

SPR is well-suited to measuring the affinity and selectivity of biomolecular interactions. It can be used for investigating association and dissociation rate constants and presenting the kinetics of biomolecular interactions. This technique can also be used for equilibrium binding analysis.

SPR  does not require additional reagents, sample preparation, or assays and has high precision for classifying protein-protein interactions.[1]

Isothermal Titration Calorimetry

ITC is a method used for the quantitative study of a range of biomolecular interactions. This technique works by measuring the heat directly that is absorbed or released in a biomolecular binding event.

The main benefit of ITC is that it can determine each binding parameter concurrently in just one experiment and no modification of binding partners is required.

Bio Layer Interferometry BLI 

BLI (biolayer interferometry) is an optical biosensing technology used for biomolecular interaction analysis. One of the key benefits of BLI is that it offers real-time label-free measurements for data analysis.

BLI studies macromolecular interactions, focusing on the interference patterns from white light reflected from the surface of the biosensor tip. It is a simple technique that measures Kon, Koff, and KD in just one rapid assay.

BLI is robust and easy to set up, it can be used for a range of samples including both crude and purified samples. This means that it can be used for a variety of investigations without needing to swap between systems for samples. Its small footprint means that it does not take up valuable space in the lab, making it more versatile than many other technologies.

BLI also allows for a broad variety of affinity values with the ability to investigate the following:

• Nanobodies
• Antibodies
• AAV
• Small molecules
• Nucleic acid
• Membrane proteins

Biomolecular Interaction Analysis from Gator Bio

Gator Bio stocks a range of BLI models suitable for biomolecular interaction analysis. It is a highly flexible, accessible, and sensitive technology that can characterize large varieties of proteins and molecules. If you would like to find out more about how our products could help with your biomolecular interaction analysis, read our dedicated page here.

[1] https://pubmed.ncbi.nlm.nih.gov/23533209/

Why is small molecule analysis important?

In pharmacology and molecular biology, “small molecules” have a molecular mass below around 900 Daltons.¹ This distinction is far from arbitrary: The smaller a molecule is, the more easily it can permeate living systems. Small molecules are better able to diffuse across cell membranes, enabling them to reach intracellular action sites and giving them generally much higher bioavailability than larger “macromolecules” such as RNA or proteins.² 

For this reason, the vast majority of pharmaceutical drugs are “small” molecules (with a few notable exceptions, such as insulin, which is a protein and consequently classed as a macromolecule).

Small molecule analysis is therefore a key concern of pharmacology and molecular biology. In this context, “small molecule analysis” generally refers not only to the identification and quantification of small molecules themselves but to the analysis of their interactions with other molecules of interest (such as receptors). Yielding information on concentration, kinetics, binding and interaction affinities, small molecule analysis is fundamental to drug discovery and biomolecular research.

What is biolayer interferometry and how does it work?

First developed in the early 21^st century, biolayer interferometry (BLI) is a relatively new technique for small molecule analysis.^3–5

BLI uses the principle of optical interference to monitor binding activity between a pair of unique biomolecules.⁶ One of these molecules – the ligand – is bound (immobilized) to the surface of a fiber optic tip which has been coated with a biocompatible matrix to enable selective binding. Once the tip is prepared, it is “dipped” into a solution containing the other molecule in the pair (the analyte).

As the analyte begins to interact with the ligand on the sensor tip, the optical thickness of the biological layer (consisting of ligand and analyte) on the surface of the sensing tip increases. Small molecule analysis is enabled by monitoring the precise thickness of this layer of interacting molecules using white light interferometry, which compares the spectral shift to that of a reference surface.

How can biolayer interferometry be used for small molecule analysis?

BLI provides real-time label-free monitoring of molecular interactions on the sensor surface by continuously measuring the thickness of the layer formed by ligand-analyte interactions. This is why BLI is such a powerful tool for small molecule analysis.

Alongside surface plasmon resonance, BFI is one of only a few widely available biosensing techniques which doesn’t require labeling. However, BFI offers a few unique advantages for small molecule analysis.

Crucially, only molecules binding to or dissociating from the sensor can shift the produced interference pattern and generate a response profile. This means that unbound molecules, changes in flow rate, or changes in the refractive index of the surrounding medium don’t influence measurements. BLI is also fluidics-free and can carry out small molecule analysis for either crude or purified samples.

BLI is sensitive enough for peptide and small molecule analysis; and, thanks to its simple operation and the use of reusable fiber-optic tips, is well-suited to parallelized high-throughput applications.

BLI Small Molecule Analysis from Gator Bio

Founded by the inventors of biolayer interferometry, Gator Bio is a world-leading producer of BLI platforms for small molecule analysis applications.⁷

Combining a 1 mm glass rod with patented optical layers and specialized biosensor surface chemistry, Gator^® BLI systems allow for high-capacity immobilization of biotinylated proteins for a wide range of molecular weights. Following immobilization, Gator^® systems enable rapid and accurate small molecule analysis, determining critical interaction parameters such as k_on, k_off, and kD for molecules down to 150 Da.

Are you interested in finding out more about the Gator BLI platform for small molecule analysis? Get in touch with us today.

References and Further Reading 

1. Dougherty, T. J. & Pucci, M. J. Antibiotic Discovery and Development. (Springer Science & Business Media, 2011).

2. Veber, D. F. et al. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 45, 2615–2623 (2002).

3. Label-free detection of biomolecular interactions using BioLayer interferometry for kinetic characterization – PubMed. https://pubmed.ncbi.nlm.nih.gov/19758119/.

4. Biosensor-based small molecule fragment screening with biolayer interferometry – PubMed. https://pubmed.ncbi.nlm.nih.gov/21660516/.

5. Biolayer Interferometry | Gator Bio. https://www.gatorbio.com/technology.

6. Apiyo, D. O. Chapter 10:Biolayer Interferometry (Octet) for Label-free Biomolecular Interaction Sensing. in Handbook of Surface Plasmon Resonance 356–397 (2017). doi:10.1039/9781788010283-00356.

7. About | Gator Bio. https://www.gatorbio.com/about.

Quantification of Biomolecules

Quantitation applications are fundamental to numerous biological research protocols and in the production of pharmaceutical-grade biomolecules. It is frequently desirable to confirm the purification of antibodies or other biomolecules to characterize biologic processes or ensure the quality of starting materials^1,2. Quantitation applications are thus key to a range of research and therapeutic protocols.

Protein Purification

With ever-growing biotechnology capabilities, protein engineering is an increasingly important aspect of both research and biological therapies. Quantitation applications are paramount in providing confidence in protein purification methodologies before protein stduies³. Similarly, quantitation applications ensure that proteins destined for pharmaceutical use conform to rigorous quality parameters to ensure patient safety. 

Expression Optimization

The majority of molecular biology experiments start with cloned DNA, which is then transferred to E.coli or a similar expression vehicle to obtain the protein of interest. To maximize the expression of the desired protein, the DNA construct must be designed to optimize the efficiency of expression by the vehicle selected. Furthermore, the purity of the DNA must be ensured through quantitation applications to increase the output of the target protein.

Adeno-associated virus (AAV) titer determination

AAV is widely used as the vector to introduce functional genes to humans with a disorder that stems from a genetic aberration. Such gene therapy is controlled by strict regulatory standards, including specifications related to vector purity and potency. The ability to accurately determine the dose of therapeutic AAV vector is thus critical to the gene therapy process. Accurate quantification of viral genome is fundamental to demonstrating purity and confirming dose⁴.

Serological testing

The determination of antigen-specific antibodies in plasma samples is an important diagnostic tool and provides important serosurveillance information during pandemic infections⁵. Analytic tests that provide quantitative results usually require complex and labor-intensive immunoassays. There is a need for a rapid, highly sensitive technique for antibody quantitation applications.

Biolayer Interferometry

These quantitation applications and more are satisfied by a novel label-free technique using biosensors — biolayer interferometry (BLI) ^6,7,8. BLI measures the interference pattern of white light reflected from the surface of a biosensor, which indicates the presence of biomolecular interactions. Used in conjunction with a standard curve of known concentrations, BLI provides a suitable tool for rapid data acquisition across numerous quantitation applications. BLI technology is suitable for quantitation applications involving complex matrices. It can be used for quantitation applications in samples that are crude supernatants or cell lysates, as well as purified proteins. 

High sensitivity is achieved across numerous quantitation applications from small molecules to large biologic complexes. Furthermore, measurements are made in real-time, so changes in biomolecule concentration can be monitored with high precision. Only target biomolecules are measured, making BLI a powerful tool for a wide range of quantitation applications. 

Gator Products for BLI Quantitation Applications

Gator offers a range of products to facilitate the use of BLI in quantitation applications. GatorPrime™ is a robust and maintenance-free BLI instrument for label-free analysis⁹. With automated biosensor loading and automated regeneration of biosensors, it offers a hands-free alternative to labor-intensive ELISA methodologies for quantitation applications. 

GatorPrime incorporates eight independent spectrometers that enable quantitation applications to be conducted simultaneously on eight samples. With the capacity for assays sizes up to 168 samples per run, the GatorPrime system represents an efficient solution for quantitation applications. The system includes quick-start modes to support quantitation applications that are carried out by non-specialist operatives. 

GatorPlus is a high-throughput device  used in quantitation, kinetics, and epitope binning. Based on bio-layer interferometry (BLI) technology, this instrument provides rapid results.

In addition, Gator provides specialized solutions to further facilitate quantitation applications¹⁰. For example, Gator™ AAVX enables the direct capture and quantitation of different serotypes of AAV in crude lysates, column eluates, cell lysates and cell culture supernatants using the CaptureSelect™anti-AAVX ligand. The Gator™ Ni-NTA Kit enables rapid and continuous quantification of His-tagged proteins without the need for Ni2+ recharging.

The Gator BLI system uses software that complies with the FDA’s code of Federal Regulations (CFR) Title 21¹¹. This is critical for quantitation applications involved in the monitoring and manufacturing of biological drugs. All data acquired is time-stamped and traceable and its enhanced audit trails, including recorded user sessions, comply with FDA guidance. The Gator system is thus suitable for use in environments where adherence to good manufacturing/laboratory practice is paramount and analyses must be CFR21-compliant. 

If you would like to find out more about how Gator Bio can help with your quantitation applications, you can read more on our website. 

References

1. Westbrook JA, et al. Proteomics Clin Appl. 2015 Apr;9(3-4):295-300. Doi: 10.1002/prca.201400120. 
2. Heegaard NH, et al. Electrophoresis. 1999 Oct;20(15-16):3122-33.
3. Lillehoj EP, Malik VS. Adv Biochem Eng Biotechnol. 1989;40:19-71.
4. Jungmann A, et al. Hum Gene Ther Methods. 2017; 28(5):235-246.
5. Dzimianski JV, et al. Sci Rep. 2020;10(1):21738.
6. Qiao SP, et al. Chembiochem. 2021 Jun 2;22(11):1974-1984.
7. Noy-Porat T, et al. STAR Protoc. 2021 Sep 15;2(4):100836.
8. Dysinger M, et al. J Immunol Methods. 2012 May 31;379(1-2):30-41.
9. Gator. https://www.gatorbio.com/products/gatorprime
10. Gator. https://www.gatorbio.com/products/biosensors-and-reagents
11. Gator. https://www.gatorbio.com/products/software

Binding kinetics have been studied for many years and make up the basis of pharmacological theory today. Whilst all pharmaceutical drugs are different, the binding kinetics have many similarities. 

The term binding kinetics refers to how quickly a compound binds to its target and the speed at which it dissociates from it. Binding kinetics measure the on-rate and the off-rate but have historically been challenging to measure. This article will explain the fundamentals of binding kinetics and how they work. 

The Importance of Binding Affinity 

The binding affinity of a drug is inextricably linked to binding kinetics. The binding affinity refers to the levels of drugs needed to occupy 50% of the target molecules at equilibrium. This number is the target occupancy, used to predict in-vivo efficacy.  

The residence time is a quantitative value referring to how long it takes for drug-receptors to reach target occupancy.  

The Importance of Binding Kinetics in Affinity Measurements 

The importance of binding kinetics is based on the fact that the time to reach equilibrium is dependent on the dissociation time. When the opposing rates are equal, a binding interaction is at equilibrium. Because association takes place first for dissociation to occur. This is why full binding kinetics data is required to effectively measure binding affinity. When using binding kinetics, meeting an equilibrium isn’t required and therefore it can be a much faster method. 

Binding Kinetics in Drug Discovery 

Accurate and fast measurement of binding affinity is critically important in the drug discovery process. If the actual affinity is above what is measured then patients may risk overdose in clinical drug trials. Similarly, if it is lower than recorded potentially life-saving drugs could be missed because of under-dosing.  

Binding kinetics differentiate medication by informing dose-response relationships. This means that physiological effectors can be appropriately counteracted by drug concentrations.  

Binding kinetics are intrinsically linked to the translation of drug action to safety, efficacy, and duration of response outcomes.  

How to Measure Binding Kinetics 

Establishing an understanding of binding kinetics is critical for developing drug molecules. To do this, equilibrium constants must be established. Koff is the dissociation constant in min^-1.  Kon is the association constant in inverse minutes multiplied by inverse concentration. KD is computed from Koff/Kon. Expressed in Molar units 

Gator Bio BLI provides a simple means of measuring kinetics. Using real-time data, binding kinetics (Kon and Koff) and affinity values (KD) can be measured. Because BLI offers insight into dissociation, association rates, and affinity value it can help predict the activity of biomolecules in vivo.  

Binding kinetics make up the foundation of pharmacological theory in the modern era. Binding kinetics is a term that is concerned with the speed at which a compound binds to a target and how quickly it dissociates from it.  

BLI (bio-layer interferometry) is an optical biosensing technology used in analyzing biomolecular interactions without requiring fluorescent labeling. BLI is one of the few widely available biosensing technologies that are label-free. BLI measures macromolecular interactions by analyzing the patterns of interference from white light reflected from a biosensor tip surface. This article discusses the benefits of BLI for measuring binding kinetics. 

What Parameters of Binding Kinetics can be Determined Using BLI? 

BLI allows for real-time determination of association rate (k_on) and dissociation rate (k_off) in molecular interaction and as such the binding kinetics. These rates provide the opportunity to understand the overall affinity (K_D) of the interaction to be calculated. This value can also be ascertained directly from the formation of concentration-dependent molecular complexes.  

Benefits of BLI 

Simplicity 

One key benefit of using BLI for binding kinetics measurements is that K_on, K_off, and K_D can be measured in one rapid assay. Detection takes place in real-time without marking biological molecules. This makes the measurement quicker and simpler than processes that require multiple assays. 

Wide Ranges 

Using BLI for binding kinetics allows for a wide range of affinity values. BLI can be used for many investigations such as nanobodies, membrane proteins, antibodies, AAV, small molecules, nucleic acids, and more.  

Compatible with a Range of Samples 

BLI is compatible with both crude and purified samples. This means it can be used in a range of investigations and there is no need to swap between systems for samples. 

No Labels Required 

Label-free techniques can monitor responses in real-time, meaning kinetic information regarding dissociation and association is accessible. They can also monitor bio-molecular interactions with native binding partners without any impediment from modified analytes and therefore more accurate biochemical data is acquired.  

BLI for Binding Kinetics 

Gator Bio software provides a range of models for data analysis. Reference subtraction, processing, and data fitting can be performed quickly. Biosensors from Gator Bio combine a 1mm diameter glass rod with patented optical layers and surface chemistry specifically built at the distal end of the biosensor. To find out more about how this technology can be used in binding kinetics applications, contact the team at Gator Bio today.  

PALO ALTO, Calif., Jan. 5, 2022 /PRNewswire/ — Drug makers, biotech companies, biologics developers and CROs will now have the much-needed 21 CFR Part11-compliant software for their GatorPrime and GatorPlus Biolayer Interferometry systems (BLI). The software announced today significantly enhances Gator Bio’s BLI solution for biologics development, which includes application-specific biosensors, Gator^® GatorOne Software and BLI systems.

“Our customers, in no uncertain terms, had told us that Gator Bio’s innovative and high-performance BLI solution would gain wider adoption in their biologics development with 21 CFR Part11 compliant software. Now it is made available. We were committed to delivering this much-needed solution, and with the release of Gator^®  Part11 Software we have delivered on our promise,” said CEO Dr. Hong Tan.

As further proof of our commitment to the Biopharma industry, we are also releasing an IQ/OQ service bundle for GatorPrime and GatorPlus system qualification that will further enhance confidence in data generated using these BLI systems. Both products are ready to ship.

About Gator Bio, Inc.

Gator Bio is a life-sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio and its sister company ET Healthcare are part of Access Medical Systems. Gator instruments and biosensors enable real-time analysis of biomolecular interactions, providing information on affinity, kinetics, concentration, epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates, providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com.

Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
[email protected]
+1 650 575 0827

Gator Bio, Inc. announced the launch of the Gator^TM SMAP probe and Gator^TM mFC probe for GatorPrime and GatorPlus biolayer interferometry (BLI) systems today. 

The company has been focused on the development and commercialization of the novel biosensors for the next generation BLI that greatly enhances the performance and cost effectiveness of this simple yet powerful analytical technology. 

“We saw gaps and challenges in drug discovery and development using BLI technology and decided to develop new surface chemistries for the probes,” said Dr. Hong Tan, CEO of Gator Bio. “We believe these new probes will significantly reduce the cost and enhance biopharma research capabilities.” 

The Gator^TM SMAP probe designed for small molecule-protein binding studies has demonstrated significantly improved sensitivity. The Gator beta users also demonstrate best-in-class performance for small peptide kinetic screening against full length of antibodies that are generally difficult to perform using traditional BLI. 

The typical antibody screening from hybridomas commonly utilizes ELISA technology. The Gator^TM mFC probe enables very high sensitivity, 5-log dynamic range, and provides a much simpler and quicker workflow than ELISA. The unique capability of regeneration up to 20 times or more without performance degradation provides a highly cost-effective solution for biopharma.

Detailed info on the Gator^TM SMAP probe and Gator^TM mFC probe along with Gator Bio’s complete portfolio of products can be found here. 

These biosensors come on the heels of the recent release of Gator^TM Flex SA Kit and Gator^TM AAVX probes.

About Gator Bio, Inc.

Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio along with its sister company ET Healthcare are part of Access Medical Systems. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration, and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com.

SOURCE Gator Bio, Inc.

Media and Investor Relations Contact:

Subodh Nimkar, Marketing Director 

[email protected]

+1 650 575 0827

Web site: https://www.gatorbio.com//

LinkedIn

PALO ALTO, Calif., Sept. 14, 2021 /PRNewswire/ — Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific application needs.

GatorPlus is a bench-top instrument for real-time label-free analysis of molecular interactions and quantitation in 96-well or 384-well microplates. The instrument offers longer walk-away time and more automation compared to GatorPrime, the first Gator instrument launched in March 2019.     

Based on Gator Bio’s proprietary technology, the Gator™ Flex SA Kit is the industry’s first ever reactivable streptavidin biosensor for BLI. It can be reactivated and reused more than 20 times without performance degradation, enabling significant cost saving for Gator system customers.

The Gator™ AAVX probe quantitates many serotypes of AAVs automatically in minutes, greatly simplifying AAV developers’ workflow. The results obtained from the Gator™ AAVX probes correlate tightly to the gold standard method.

Gator Bio was founded by Dr. Hong Tan and Mr. Robert Zuk, the pioneers of biolayer interferometry. The company has been focused on development and commercialization of the next generation BLI that greatly enhances the performance and cost effectiveness of this simple yet powerful analytical technology.

In addition to the newly introduced Gator™ Flex SA Kit and Gator™ AAVX probes, Gator Bio offers a wide range of products, including the highly sensitive SMAP biosensor and the regenerable mouse Fc capture biosensor. The Gator systems and associated biosensors provide convenient kinetic analysis and concentration determination for the development of antibody and protein therapeutics.

“We saw problems and shortcomings with the original BLI technology, so we decided to come back to close the gaps with new ways to realize BLI” said Dr. Hong Tan, CEO of Gator Bio. “Our objective is to enable the most effective and efficient BLI systems for scientists. “

Detailed info on the Gator™ Flex SA Kit and Gator™ AAVX probes along with Gator Bio’s complete portfolio of products can be found here. You can also hear inventors talk about the technology and the Gator Bio’s vision.

About Gator Bio, Inc.

Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio along with its sister company ET Healthcare are part of Access Medical Systems. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com.

Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
[email protected]
+1 650 575 827